Cannabix Achieves New Plateau with its FAIMS Marijuana Breathalyzer Technology
October 05 2020 - 8:44AM
Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (the
“Company or Cannabix”) developer of marijuana breathalyzer devices
for law enforcement and the workplace reports that engineers have
achieved new, much higher levels of resolving power using a new PCB
design and the latest mosfet chip technology leading to the highest
level of molecular specificity to date with its Cannabix FAIMS Beta
3.2 circuit. The Company also reports the design of a significantly
more compact FAIMS circuit board, paving the way for a smaller
device footprint relative to previous versions, enhancing
portability. Cannabix is using its FAIMS technology to isolate and
detect ∆9-tetrahydrocannabinol (“THC”), a non-volatile compound, in
breath. The Cannabix FAIMS marijuana breathalyzer device uses ion
mobility filtering techniques (related to mass spectrometry – the
gold standard analytical technique for molecular detection).
Cannabix Technologies is on the forefront in research and
development to create point-of-care breath testing technologies for
the detection of THC - the psychoactive component of marijuana that
causes impairment.
Rav Mlait, CEO stated, “The Company believes that
these latest developments with the Company’s FAIMS based detection
system, open up areas of analytical chemistry that diagnostic
fields have been seeking for chemical analysis. Our team has made
significant technological strides, even under covid restrictions
over the last number of months.”
The Company also reports that it has recently
participated in an information session (highlighting the Company’s
breath testing technologies) with a group of transportation,
safety, policy experts primarily from the northeastern region of
the US.
About Cannabix Technologies Inc.
Cannabix Technologies Inc. is a leader in marijuana
breathalyzer development for law enforcement and the workplace.
Cannabix has established breath testing technologies in the pursuit
of bringing accurate, durable, portable tools to market to enable
detection of marijuana-impaired driving offences on roads at a time
when marijuana is becoming legal in many global jurisdictions.
Cannabix is working to develop drug-testing devices that will
detect THC- the psychoactive component of marijuana that causes
intoxication- using breath samples. In particular, Cannabix is
focused on developing breath testing devices for detection of
recent use of THC, in contrast to urine testing for THC metabolite
that requires an invasive collection and reflects usage, days or
even weeks earlier. The devices will also be useful for other
practical applications such as testing employees in the workplace
where impairment by THC can be hazardous.
We seek Safe Harbor.
On behalf of the Board of Directors
“Rav Mlait”
CEOCannabix Technologies Inc.
For further information, contact the Company at
info@cannabixtechnologies.com
The CSE has not reviewed and does not accept
responsibility for the adequacy or accuracy of this release.
Cautionary Statement Regarding Forward-Looking
StatementsThis press release contains forward-looking information
that involves various risks and uncertainties regarding future
events. Such forward-looking information can include without
limitation statements based on current expectations involving a
number of risks and uncertainties and are not guarantees of future
performance of the Company, such as final development of a
commercial or prototype product(s), successful trial or pilot of
company technologies, no assurance that commercial sales of any
kind actually materialize; no assurance the Company will have
sufficient funds to complete product development. There are
numerous risks and uncertainties that could cause actual results
and the Company’s plans and objectives to differ materially from
those expressed in the forward-looking information, including: (i)
adverse market conditions; (ii) risks regarding protection of
proprietary technology; (iii) the ability of the Company to
complete financings; (iv) the ability of the Company to develop and
market its future product; and (v) risks regarding government
regulation, managing and maintaining growth, the effect of adverse
publicity, litigation, competition and other factors which may be
identified from time to time in the Company's public announcements
and filings. There is no assurance that the marijuana breathalyzer
business will provide any benefit to the Company, and no assurance
that any proposed new products will be built or proceed. There is
no assurance that existing “patent pending” technologies licensed
by the Company will receive patent status by regulatory
authorities. The Company is not currently selling commercial
breathalyzers. Actual results and future events could differ
materially from those anticipated in such information. These and
all subsequent written and oral forward-looking information are
based on estimates and opinions of management on the dates they are
made and are expressly qualified in their entirety by this notice.
Except as required by law, the Company does not intend to update
these forward-looking statements.
Cannabix Technologies (CSE:BLO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cannabix Technologies (CSE:BLO)
Historical Stock Chart
From Sep 2023 to Sep 2024